We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Itaconix Plc | LSE:ITX | London | Ordinary Share | GB00BPK3YZ68 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 157.50 | 150.00 | 165.00 | 157.50 | 157.50 | 157.50 | 1,717 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 5.6M | -2.46M | -0.1826 | -8.63 | 21.24M |
TIDMITX
RNS Number : 4791F
Itaconix PLC
18 May 2017
18 May 2017
Itaconix plc ("Itaconix" or the "Group")
Operational Update
Itaconix, a leading designer and manufacturer of specialty polymers, announces that following the acquisition and integration of Itaconix Corporation in the USA, it is implementing operational changes to the Group. Resources will be more focused on successfully executing the Group's strategy to launch and grow the sales of its products, primarily in the global personal care and homecare markets, including the development of application data that provides clear evidence of the material benefits of using Itaconix's products and how they can be best formulated into end consumer products.
Given the Group's established product portfolio and evolving sales and marketing focus, its need for new product development is becoming more defined and targeted to customer requirements. Accordingly, it is now appropriate to resize the R&D team, which will result in operational efficiencies. Whilst the full financial effect of these changes will not be achieved immediately, with the net cash impact being broadly neutral in 2017, the positive net cash impact is expected to be approximately GBP1m per annum from 2018.
"The re-balancing of our business is an important step in establishing and growing our product sales and increasing operational efficiencies." said Dr. Kevin Matthews, CEO of Itaconix. "In the short to medium term we are highly focused on our sales and marketing efforts to drive our existing product portfolio into market, and the new structure does mean that some of our team are leaving us. In particular, I would like to thank Dr David Pears our CTO since January 2008 for his unrelenting efforts; David will be retiring from the business at the end of May 2018 after more than 10 years of service. The board firmly believes that an increased effort and focus on product commercialisation is the right direction of travel for the business and that the reduction in our cost base will help accelerate Itaconix's path to profitability.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Ends
For further information please contact:
+44 (0) 1244 283 Itaconix 500 Kevin Matthews / Rob Cridland +44 (0) 207 496 N+1 Singer 3000 Richard Lindley / Liz Yong (Corporate Finance) Nick Owen (Corporate Broking)
Hudson Sandler
Charlie Jack / Emily Dillon +44 (0) 207 796 4133
About Itaconix
Itaconix is developing proprietary ingredients that meet the performance and price needs of its customers and offers them improved safety and sustainability, thereby helping to deliver on the global sustainability agenda, with particular emphasis on the Personal Care and Homecare markets.
www.itaconix.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTARMRTMBIBBMR
(END) Dow Jones Newswires
May 18, 2017 02:00 ET (06:00 GMT)
1 Year Itaconix Chart |
1 Month Itaconix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions